Facebook

SOSTENIAMO
PROGETTI CONCRETI

CONTRO MALATTIE
E TUMORI DEL PANCREAS

Immagine generata con AI. Scenario simulato a fini illustrativi.

Da oltre vent’anni il nostro sogno è concreto: trovare una cura definitiva per le malattie e i tumori pancreatici. Per questo finanziamo borse di ricerca, promuoviamo giovani talenti e investiamo fondi per nuove tecnologie che possano fare la differenza nella vita di oltre 14.000 italiani.

In vent’anni, siamo arrivati fino a qui.
Con il tuo aiuto, possiamo arrivare ovunque.

DONA ORA

FIMP oltre ai Progetti portati avanti in convenzione con il Ministero della Salute ha erogato contributi/donazioni liberali in favore di:

  • Borse di studio in memoria di pazienti.

  • Personale dedicato alle attività di ricerca nell’ambito 
della patologia oncologica del pancreas.
  • Progetti di ricerca scientifica.

  • Eventi scientifici o congressi.

  • Organizzazione eventi formativi/corsi.

  • Patrocinio di eventi scientifici sul tema.

  • Premi. 

  • Associazione a supporto di pazienti e parenti.

  • Altre Iniziative di informazione-sensibilizzazione 
sulle malattie del pancreas.

Le nostre pubblicazioni

Anno 2020
  1. Paiella S, Landoni L, Rota R, Valenti M, Elio G, Crino SF, Manfrin E, Parisi A, Cingarlini S, D’Onofrio M, Scarpa A, Lawlor RT, Bernardoni L, Capelli P, Nessi C, Miotto M, Gabbrielli A, Bassi C, Salvia R. Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases. Endoscopy 2020, 52:988–994.

  1. Crino SF, Di Mitri R, Nguyen NQ, Tarantino I, de Nucci G, Deprez PH, Carrara S, Kitano M, Shami VM, Fernandez-Esparrach G, Poley JW, Baldaque-Silva F, Itoi T, Manfrin E, Bernardoni L, Gabbrielli A, Conte E, Unti E, Naidu J, Ruszkiewicz A, Amata M, Liotta R, Manes G, Di Nuovo F, Borbath I, Komuta M, Lamonaca L, Rahal D, Hatamaru K, Itonaga M, Rizzatti G, Costamagna G, Inzani F, Curatolo M, Strand DS, Wang AY, Gines A, Sendino O, Signoretti M, van Driel L, Dolapcsiev K, Matsunami Y, van der Merwe S, van Malenstein H, Locatelli F, Correale L, Scarpa A, Larghi A: Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. Gastroenterology 2021, 161(3):899-909 e895.

  2. Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, Gregori D, Golan T, Braconi C, Froeling FEM, Milella M, Scarpa A, Pea A, Malleo G, Salvia R, Bassi C, Chang DK, Biankin AV: Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. J Clin Oncol 2021, 39(23):2617-2631.

  3. Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M: Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open 2021, 6(5):100238.

  4. Lawlor RT, Mattiolo P, Mafficini A, Hong SM, Piredda ML, Taormina SV, Malleo G, Marchegiani G, Pea A, Salvia R, Kryklyva V, Shin JI, Brosens LA, Milella M, Scarpa A, Luchini C: Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers (Basel) 2021, 13(13).

  5. Luchini C, Grant RC, Scarpa A, Gallinger S: Microsatellite instability/mismatch repair deficiency in pancreatic cancers: the same or different? Gut 2021, 70(10):1809-1811.

  6. Luchini C, Mafficini A, Chatterjee D, Piredda ML, Sciammarella C, Navale P, Malleo G, Mattiolo P, Marchegiani G, Pea A, Salvia R, Brosens LA, Paolino G, Mastrosimini MG, Silvestris N, Milella M, Cheng L, Adsay VN, Lawlor RT, Scarpa A: Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. Virchows Arch 2021.

  7. Carbone C, Piro G, Agostini A, Delfino P, De Sanctis F, Nasca V, Spallotta F, Sette C, Martini M, Ugel S, Corbo V, Cappello P, Bria E, Scarpa A, Tortora G: Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. J Immunother Cancer 2021, 9(9).

  8. Osuna de la Pena D, Trabulo SMD, Collin E, Liu Y, Sharma S, Tatari M, Behrens D, Erkan M, Lawlor RT, Scarpa A, Heeschen C, Mata A, Loessner D: Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Nat Commun 2021, 12(1):5623.

  9. Goulart MR, Watt J, Siddiqui I, Lawlor RT, Imrali A, Hughes C, Saad A, ChinAleong J, Hurt C, Cox C, Salvia R, Mantovani A, Crnogorac-Jurcevic T, Mukherjee S, Scarpa A, Allavena P, Kocher HM: Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. NPJ Precis Oncol 2021, 5(1):61.

  10. Lawlor RT, Mafficini A, Sciammarella C, Cantu C, Rusev BC, Piredda ML, Antonello D, Grimaldi S, Bonizzato G, Sperandio N, Marchegiani G, Malleo G, Pea A, Salvia R, Mombello A, Mazzoleni G, Nottegar A, Hanspeter E, Riva G, Tomezzoli A, Bencivenga M, de Manzoni G, Pedron S, Paolino G, Mattiolo P, Brosens LA, Silvestris N, Fassan M, Cooke SL, Beer PA, Milella M, Adsay VN, Cheng L, Scarpa A, Luchini C: Genomic characterization of hepatoid tumors: context matters. Hum Pathol 2021, 118:30-41.

  11. Mafficini A, Lawlor RT, Ghimenton C, Antonello D, Cantu C, Paolino G, Nottegar A, Piredda ML, Salvia R, Milella M, Dei Tos AP, Fassan M, Scarpa A, Luchini C: Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling. Genes (Basel) 2021, 12(4).

  12. Silvestris N, Argentiero A, Brunetti O, Sonnessa M, Colonna F, Delcuratolo S, Luchini C, Scarpa A, Lonardi S, Nappo F, Fassan M, Solimando AG, Fucci L, Saponaro C: PD-L1 and Notch as novel biomarkers in Pancreatic Sarcomatoid Carcinoma: a pilot study. Expert Opin Ther Targets 2021.

  13. Hackeng WM, Brosens LAA, Kim JY, O’Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD: Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut 2021.

  14. Luchini C, Lawlor RT, Bersani S, Vicentini C, Paolino G, Mattiolo P, Pea A, Cingarlini S, Milella M, Scarpa A: Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? Curr Oncol Rep 2021, 23(9):106.

  15. Lakis V, Lawlor RT, Newell F, Patch AM, Mafficini A, Sadanandam A, Koufariotis LT, Johnston RL, Leonard C, Wood S, Rusev B, Corbo V, Luchini C, Cingarlini S, Landoni L, Salvia R, Milella M, Chang D, Bailey P, Jamieson NB, Duthie F, Gingras MC, Muzny DM, Wheeler DA, Gibbs RA, Milione M, Apgi, Net ARC, Pederzoli P, Samra JS, Gill AJ, Johns AL, Pearson JV, Biankin AV, Grimmond SM, Waddell N, Nones K, Scarpa A: DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Commun Biol 2021, 4(1):155.

  16. Casolino R, Biankin AV, PanCaCovid-19 Study G: Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Gastroenterology 2021, 161(6):1758-1763.

  17. Paiella S, Landoni L, Tebaldi S, Zuffante M, Salgarello M, Cingarlini S, D’Onofrio M, Parisi A, Deiro G, Manfrin E, Bianchi B, Montagnini G, Crino SF, Bassi C, Salvia R: Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases. Neuroendocrinology 2021.

  18. Giuliani T, De Pastena M, Paiella S, Marchegiani G, Landoni L, Festini M, Ramera M, Marinelli V, Casetti L, Esposito A, Bassi C, Salvia R: Pancreatic Enucleation Patients Share the Same Quality of Life as the General Population at Long-Term Follow-Up: A Propensity-Score Matched Analysis. Ann Surg 2021.

  19. Salvia R, Marchegiani G, Andrianello S, Balduzzi A, Masini G, Casetti L, Esposito A, Landoni L, Malleo G, Paiella S, Tuveri M, Bassi C: Redefining the Role of Drain Amylase Value for a Risk-Based Drain Management after Pancreaticoduodenectomy: Early Drain Removal Still Is Beneficial. J Gastrointest Surg 2021, 25(6):1461-1470.

  20. Trestini I, Carbognin L, Peretti U, Sperduti I, Caldart A, Tregnago D, Avancini A, Auriemma A, Orsi G, Pilotto S, Frulloni L, Capurso G, Bria E, Reni M, Tortora G, Milella M: Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Front Oncol2021, 11:688889.

  1. Mattiolo P, Scarpa A, Luchini C: Hepatoid tumors of the gastrointestinal/pancreatobiliary district: morphology, immunohistochemistry, and molecular profiles. Hum Pathol 2022. doi: 10.1016/j.humpath.2022.06.011. Online ahead of print.

  2.  Mattiolo P, Mafficini A, Lawlor RT, Marchegiani G, Malleo G, Pea A, Salvia R, Piccoli P, Sciammarella C, Santonicco N, Parisi A, Silvestris N, Milella M, Adsay V, Scarpa A, Luchini C: “Pure” hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms. Virchows Arch 2022, 481(1):41-47.

  3. Gkountakos A, Mafficini A, Lou E, Malleo G, Salvia R, Calicchia M, Silvestris N, Racila E, Amin K, Veronese N, Brunetti O, Antonini P, Ingravallo G, Mattiolo P, Saponaro C, Nappo F, Simbolo M, Bariani E, Lonardi S, Fassan M, Milella M, Lawlor RT, Scarpa A, Luchini C: Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. Hum Pathol 2022, 128:124-133.

  4. Gkountakos A, Simbolo M, Bariani E, Scarpa A, Luchini C: Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology. Int J Mol Sci 2022, 23(3).

  5. Paolino G, Esposito I, Hong SM, Basturk O, Mattiolo P, Kaneko T, Veronese N, Scarpa A, Adsay V, Luchini C: Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors. Histopathology 2022, 81(3):297-309.

  6. Mafficini A, Simbolo M, Shibata T, Hong SM, Pea A, Brosens LA, Cheng L, Antonello D, Sciammarella C, Cantu C, Mattiolo P, Taormina SV, Malleo G, Marchegiani G, Sereni E, Corbo V, Paolino G, Ciaparrone C, Hiraoka N, Pallaoro D, Jansen C, Milella M, Salvia R, Lawlor RT, Adsay V, Scarpa A, Luchini C: Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma. Mod Pathol 2022. doi: 10.1038/s41379-022-01143-2. Online ahead of print.

  7. Pollini T, Adsay V, Capurso G, Dal Molin M, Esposito I, Hruban R, Luchini C, Maggino L, Matthaei H, Marchegiani G, Scarpa A, Wood LD, Bassi C, Salvia R, Mino-Kenudson M, Maker AV: The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms. Lancet Gastroenterol Hepatol 2022.doi: 10.1016/S2468-1253(22)00235-7. Online ahead of print.

  8. Malleo G, Maggino L, Casciani F, Lionetto G, Nobile S, Lazzarin G, Paiella S, Esposito A, Capelli P, Luchini C, Scarpa A, Bassi C, Salvia R: Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol. Ann Surg Oncol 2022, 29(6):3477-3488.

  9. Mattiolo P, Kryklyva V, Brosens LA, Mafficini A, Lawlor RT, Milella M, Scarpa A, Corbo V, Luchini C: Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Expert Opin Ther Targets 2022, 26(1):1-4.

  10. Luchini C, Scarpa A: Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications. Hum Pathol 2022. doi: 10.1016/j.humpath.2022.06.009. Online ahead of print.

  11. Milella M, Luchini C, Lawlor RT, Johns AL, Casolino R, Yoshino T, Biankin AV, Icgc A: ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Lancet Oncol 2022, 23(1):25-26.

  12. Milella M, Lawlor RT, Luchini C, Johns AL, Icgc A, Casolino R, Yoshino T, Biankin AV, Scarpa A: ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. Lancet Oncol 2022, 23(8):991-992.

  13. Alors-Perez E, Blazquez-Encinas R, Alcala S, Viyuela-Garcia C, Pedraza-Arevalo S, Herrero-Aguayo V, Jimenez-Vacas JM, Mafficini A, Sanchez-Frias ME, Cano MT, Abollo-Jimenez F, Marin-Sanz JA, Cabezas-Sainz P, Lawlor RT, Luchini C, Sanchez L, Sanchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sanchez A, Ibanez-Costa A, Sainz B, Jr., Luque RM, Castano JP: Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J Exp Clin Cancer Res 2021, 40(1):382.

  14. De Santis MC, Gozzelino L, Margaria JP, Costamagna A, Ratto E, Gulluni F, Di Gregorio E, Mina E, Lorito N, Bacci M, Lattanzio R, Sala G, Cappello P, Novelli F, Giovannetti E, Vicentini C, Andreani S, Delfino P, Corbo V, Scarpa A, Porporato PE, Morandi A, Hirsch E, Martini M: Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Gut 2022. doi: 10.1136/gutjnl-2021-325117. Online ahead of print

  15. Bannone E, Marchegiani G, Perri G, Procida G, Vacca PG, Cattelani A, Salvia R, Bassi C: Postoperative serum hyperamylasemia (POH) predicts additional morbidity after pancreatoduodenectomy: It is not all about pancreatic fistula. Surgery 2022, 172(2):715-722.

  16. Giuliani T, Marchegiani G, Di Gioia A, Amadori B, Perri G, Salvia R, Bassi C: Patterns of mortality after pancreatoduodenectomy: A root cause, day-to-day analysis. Surgery 2022, 172(1):329-335.

  17. Chiaravalli M, Spring A, Agostini A, Piro G, Carbone C, Tortora G: Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers. Cells 2022, 11(19).

  18. Piro G., Carbone C., Agostini A., Esposito A., De Pizzol M., Novelli R., Allegretti M., Aramini A, Caggiano A., Granitto A., De Sanctis F., Ugel S., Corbo V., Martini M., Sacrpa A., Tortora G. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. British Journal of Cancer 2022. https://doi.org/10.1038/s41416-022-02028-6

  19. Paiella S, Landoni L, Tebaldi S, Zuffante M, Salgarello M, Cingarlini S, D’Onofrio M, Parisi A, Deiro G, Manfrin E, Bianchi B, Montagnini G, Crinò SF, Bassi C, Salvia R. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases. Neuroendocrinology 2022.112(2):143-152.

  20. Luchini C, Pea A, Scarpa A: Artificial intelligence in oncology: current applications and future perspectives. Br J Cancer 2022, 126(1):4-9